Tisenc Medical Closes on ￥80M Series B Financing

According to 36Kr.com, Shenzhen Tisenc Medical Devices Co., Ltd. ("Tisenc Medical"), a provider of POCT (Point Care of internal Care Testing) Chemiluminescence Immunology (CLIA) systems, has completed ￥80 million (US$11.6 million) series B financing, co-led by Elink  CapitaI and TF Capital, with participation from Qiming Venture Partners.

Previously, Tisenc Medical has totally got investment of more than 52 million yuan, including the angel round of tens of millions yuan led by Hangzhou Rock Grass Investment, ￥40 million series A round exclusively from Qiming Venture Partners.

Founded in 2015, Shenzhen Tisenc Medical is a Sino-foreign joint venture. Located in Shenzhen Guangdong, Tisenc Medical is committed to the developing, manufacturing and global sales of CLIA systems. The company provides the products of the CLIA system, high-level POCT system, and molecular diagnostics solutions.

Tisenc Medical has successfully developed the ACCRE system, a single-used automated chemiluminescence immunoassay analyzer, which consists of both the flexible operation of small POCT products and the quality level of chemiluminescence detection systems. Based on the innovative nature of the two, the ACCRE system can satisfy the needs of various customers including emergency departments, STAT laboratories and core laboratories. 

TF Capital focuses on investment in the life sciences industry, including biotechnology, therapeutics & pharmaceuticals, drug delivery, medical device & instruments, and medical service, primarily investing in early-stage companies with high potential.  

Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. 

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.